CATALYST PHARMACEUTICALS, INC.
CPRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CPRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with approved products FIRDAPSE and AGAMREE and a strong cash position.
Key risk: FIRDAPSE patent expiry
BioSniper Score
Based on 5 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 6 pipeline candidates · 5 clinical trials · 2 catalysts · 4 FDA decisions for CATALYST PHARMACEUTICALS, INC..
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with approved products FIRDAPSE and AGAMREE and a strong cash position.
- Cash and equivalents of $755.9M as of 2026-03-31 [sec].
- Total revenue of $149.4M and net income of $63.7M for the quarter ended 2026-03-31 [sec].
- Shareholders' equity of $954.3M as of 2026-03-31 [sec].
- FIRDAPSE net product revenues of approximately $306M in 2024, exceeding the 2024 goal [sec · filed 2025-04-11].
- AGAMREE net product revenues of approximately $46M in 2024, exceeding the 2024 goal of $20M [sec · filed 2025-04-11].
What works
- Strong cash position of $755.9M provides financial flexibility for business development and operations [sec].
- FIRDAPSE and AGAMREE both exceeded 2024 net product revenue goals, indicating solid commercial execution [sec · filed 2025-04-11].
- Total revenues in 2024 of approximately $492M exceeded the 2024 goal by $17M [sec · filed 2025-04-11].
- Company is actively exploring acquisition opportunities to broaden its rare disease portfolio [sec_mda · as of 2026-02-25].
What to weigh
- Patent expiry for FIRDAPSE is scheduled for 2037-02-25, which could eventually expose the product to generic competition [catalyst].
- Patent expiry for AGAMREE is scheduled for 2040-07-16, representing a long-term exclusivity risk [catalyst].
- Potential tariffs on pharmaceutical imports could adversely affect the business, as noted in SEC filings [sec_mda · as of 2026-05-11].
- The company faces risks related to consummating acquisitions and obtaining stockholder approval for transactions [sec · filed 2026-06-23].
From the filings
Quoted directly from source documents.
FIRDAPSE net product revenues exceeded 2024 goal
“The Company's net product revenues in 2024 for FIRDAPSE®were approximately $306 million, exceeding the 2024 goal of $301.6 million.”
SEC filings · April 11, 2025
AGAMREE net product revenues exceeded 2024 goal
“The Company's net product revenues in 2024 for AGAMREE®were approximately $46 million, exceeding the 2024 goal of $20 million.”
SEC filings · April 11, 2025
Total revenues exceeded 2024 goal
“The Company achieved total revenues in 2024 of approximately $492 million, exceeding the 2024 goal by $17 million.”
SEC filings · April 11, 2025
Company exploring acquisition opportunities
“we are currently exploring several additional potential opportunities to acquire companies with commercial drug products”
SEC MD&A · February 25, 2026
Catalyst timeline
- 2037-02-25 · Patent_Expiry · FIRDAPSE — Patent/Exclusivity Expiry: FIRDAPSE — FIRDAPSE's patent/exclusivity expiry could open the door for generic competition, potentially impacting revenue.
- 2040-07-16 · Patent_Expiry · AGAMREE — Patent/Exclusivity Expiry: AGAMREE — AGAMREE's patent/exclusivity expiry is a long-term event that may eventually affect market exclusivity.
Risks & what to watch (4)›
Key risks
- FIRDAPSE patent expiry — Patent/exclusivity expiry for FIRDAPSE on 2037-02-25, which could lead to generic competition [catalyst].
- AGAMREE patent expiry — Patent/exclusivity expiry for AGAMREE on 2040-07-16, a long-term risk to revenue exclusivity [catalyst].
- Potential pharmaceutical tariffs — U.S. administration signaled potential tariffs on pharmaceutical imports, which could adversely affect business [sec_mda · as of 2026-05-11].
- Acquisition and merger risks — Risks include failure to consummate transactions, obtain stockholder approval, or competing acquisition proposals [sec · filed 2026-06-23].
What to watch
- Topline results from Phase 1 study of AGAMREE announced on June 30, 2026 [sec · filed 2026-06-30].
- Business development progress, including potential acquisitions of rare disease assets [sec_mda · as of 2026-02-25].
- Impact of potential pharmaceutical tariffs on operations and supply chain [sec_mda · as of 2026-05-11].
- FIRDAPSE and AGAMREE revenue trends and market share in upcoming quarterly reports.
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run CATALYST PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CATALYST PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.13 · 4% dilution
Lead: Approved
6 candidates
2 upcoming, next in ~3832d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
379
Total value held
$2.70B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 18,774,530 | $464.9M |
| vanguard capital management llc | 10,245,332 | $253.7M |
| state street corp | 6,863,060 | $169.9M |
| american century companies inc | 4,138,416 | $102.5M |
| janus henderson group plc | 3,997,750 | $99.0M |
| deerfield management company, l.p. | 3,943,600 | $97.6M |
| dimensional fund advisors lp | 3,429,615 | $84.9M |
| bank of america corp /de/ | 3,036,546 | $75.2M |
| geode capital management, llc | 2,972,402 | $73.6M |
| morgan stanley | 2,687,299 | $66.5M |
Showing top 10 of 379 institutional holders of CATALYST PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 7.9%
- Days to cover
- 4.3
- Shares short
- 7,838,703
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CPRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for CATALYST PHARMACEUTICALS, INC.?
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with approved products FIRDAPSE and AGAMREE and a strong cash position.
What is CATALYST PHARMACEUTICALS, INC.'s lead drug candidate?
CATALYST PHARMACEUTICALS, INC.'s most advanced tracked candidate is agamree (Approved) for Duchenne muscular dystrophy (DMD).
What is CATALYST PHARMACEUTICALS, INC.'s next catalyst?
CATALYST PHARMACEUTICALS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: FIRDAPSE" — expected February 25, 2037.
Who is the CEO of CATALYST PHARMACEUTICALS, INC.?
Mr. Richard John Daly M.B.A. is the chief executive officer of CATALYST PHARMACEUTICALS, INC. (CPRX).
Where is CATALYST PHARMACEUTICALS, INC. headquartered?
CATALYST PHARMACEUTICALS, INC. (CPRX) is headquartered in Coral Gables, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.